| Literature DB >> 31512502 |
Jianwei Xu1,2,3, Zhanhui Feng4,3, Xianyao Wang2, Ying Xiong5, Lan Wang4, Lan Ye5, Huanxiang Zhang1.
Abstract
In this study, we investigated how human umbilical cord mesenchymal stem cells exerted a neuroprotective effect via antiapoptotic mechanisms in a neonatal hypoxic-ischemic encephalopathy rat model. A total of 78 10-day old (P10) rats were used. After human umbilical cord mesenchymal stem cells were collected from human umbilical cords and amplified in culture, they were administered to rat subjects 1 h after induced hypoxic-ischemic encephalopathy treatment. The short-term (48 h) and long-term (28 day) outcomes were evaluated after human umbilical cord mesenchymal stem cells treatment using neurobehavioral function assessment. Triphenyltetrazolium chloride monohydrate staining was performed at 48 h. Beclin-2 and caspase-3 levels were evaluated with Western blot and real time polymerase chain reaction at 48 h. Human umbilical cord mesenchymal stem cells were collected and administrated to hypoxic-ischemic encephalopathy pups by intracerebroventricular injection. Hypoxic-ischemic encephalopathy typically induced significant delay in development and caused impairment in both cognitive and motor functions in rat subjects. Human umbilical cord mesenchymal stem cells were shown to ameliorate hypoxic-ischemic encephalopathy-induced damage and improve both cognitive and motor functions. Although hypoxic-ischemic encephalopathy induced significant expression of caspase-3 and Beclin-2, human umbilical cord mesenchymal stem cells decreased the expression of both of them. Human umbilical cord mesenchymal stem cells may serve as a potential treatment to ameliorate brain injury in hypoxic-ischemic encephalopathy patients.Entities:
Keywords: Beclin-2; apoptosis; caspase-3; hUC-MSCs; hypoxic-ischemic encephalopathy (HIE)
Year: 2019 PMID: 31512502 PMCID: PMC6923563 DOI: 10.1177/0963689719874769
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064
Fig 1.Human umbilical cord mesenchymal stem cell (hUC-MSCs) morphology and MSC surface markers (CD44+, CD105+, CD90+, and CD73+). These indicate the biological characteristics of mesenchymal stem cells. (a) Long spindle-shaped phenotype of hUC-MSCs. (b) Expression of hUC-MSCs surface markers CD44+, CD105+. (c) Expression of hUC-MSCs surface markers CD90+,CD73+. (d) Expression levels of NOT-hUC-MSCs surface markers were very low. Scale bar = 50 μm. FSC (forward scatter), PE (dyestuff).
Fig 2.Representative TCC stained brain sections (a) and triphenyltetrazolium chloride monohydrate (TTC) analysis (b) of 48 h post-hypoxic-ischemic encephalopathy (HIE) with human umbilical cord mesenchymal stem cell (hUC-MSC) treatment. Tilt table test (c) and righting reflex (d) of 48 h post-HIE with hUC-MSC treatment. Data are presented as mean±SD. *p<0.05 vs sham, #p<0.05, p<0.05 vs vehicle, n=10 per group, difference between groups were evaluated by one-way analysis of variance (ANOVA), followed by Tukey’s test.
Fig 3.Human umbilical cord mesenchymal stem cell (hUC-MSC) administration ameliorated long-term neurological deficits. (a) Swimming distance; (b) percentage of time in target quadrant; (c) foot fault. Data are presented as mean±SD, *p<0.05, vs sham, # vs vehicle, n=10 per group, difference between groups were evaluated by one-way analysis of variance (ANOVA), followed by Tukey’s test.
Fig 4.Expression characteristic of Beclin-2 and caspase-3. (a) Endogenous Beclin-2 mRNA and caspase-3 mRNA were significantly upregulated 48 h post-hypoxic-ischemic encephalopathy (HIE). (*p< 0.05), (n=6 per group). Data are expressed as mean ± SD. (b) Representative bands of NHE1 protein. (c) Endogenous Beclin-2 protein and caspase-3 protein increased significantly 48 h post-HIE. (*p< 0.05). Data are expressed as mean±SD, (n=6 per group).